期刊
REVISTA ESPANOLA DE QUIMIOTERAPIA
卷 35, 期 2, 页码 115-130出版社
SOCIEDAD ESPANOLA QUIMIOTERAPIA
DOI: 10.37201/req/158.2021
关键词
COVID; 19; SARS; CoV2; treatment; Remdesivir; Favipiravir; Molnupiravir; PF-07321332; Paxlovid; convalescent plasma; Sotrovimab; Banlanivimab; Etesevimab; Casirivimab; Imdevinab; AZD7442; Ciganilmab; Tixagevimab; Evusheld; BRII-196; BRII-198; Dexamethasone; Corticosteroids; Tocilizumab; Sarilumab; Anakinra; Canakinumab; Baricitinib; Tofacitinib; Ruxolitinib; Adalimumab; Certolizumab; Infliximab; Etanercept; Golimumab; Itolizumab; Ravulizumab; Lemilumab; Ivermectin; Colchicine; Vitamin D; Metformin; Fluvoxamine; Azithromycin; Hydroxychloroquine; Lopinavir/ Ritonavir
The early maturity and effectiveness of the developed COVID-19 vaccines have been the most significant and life-saving breakthrough against the pandemic. Despite the development of vaccines, there has been a continuous search for therapeutic drugs throughout the pandemic. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid aims to provide an early, simplified, and critical approach to these new drugs, developments in immunotherapy, and known immune response modulators effective against the virus to help understand the current situation.
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据